Back to Journals » Oncolytic Virotherapy » Volume 5

Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy

Authors Guan M, Ma Y, Shah SR, Romano G

Received 6 November 2015

Accepted for publication 3 March 2016

Published 21 June 2016 Volume 2016:5 Pages 35—43


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati

Mingxu Guan,1 Yanping Ma,2 Sahil Rajesh Shah,3 Gaetano Romano3

1Virology, Research and Development, Zoetis Inc., Kalamazoo, MI, USA; 2Virology Laboratory, Shengjing Hospital, China Medical University, Shenyang, Liaoning, People's Republic China; 3Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, USA

Abstract: Biomarkers associated with thyroid malignant neoplasm (TMN) have been widely applied in clinical diagnosis and in research oncological programs. The identification of novel TMN biomarkers has greatly improved the efficacy of clinical diagnosis. A more accurate diagnosis may lead to better clinical outcomes and effective treatments. However, the major deficiency of conventional chemotherapy and radiotherapy is lack of specificity. Due to the macrokinetic interactions, adverse side effects will occur, including chemotherapy and radiotherapy resistance. Therefore, a new treatment is urgently needed. As an alternative approach, oncolytic virotherapy may represent an opportunity for treatment strategies that can more specifically target tumor cells. In most cases, viral entry requires the expression of specific receptors on the surface of the host cell. Currently, molecular virologists and gene therapists are working on engineering oncolytic viruses with altered tropism for the specific targeting of malignant cells. This review focuses on the strategy of biomarkers for the production of novel TMN oncolytic therapeutics, which may improve the specificity of targeting of tumor cells and limit adverse effects in patients.

Keywords: thyroid malignancy neoplasm, biomarkers, oncolytic virotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]